Delving into the Latest Updates on XINOGEN （HONG KONG） PHARMA CO., LIMITED with Synapse

Overview

Tags

Nervous System Diseases

Neoplasms

Skin and Musculoskeletal Diseases

Peptide drug conjugates

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Peptide drug conjugates	1

Top 5 Target	Count

Tubulin	1

比较两组的总生存期（OS）；CNS（软脑膜和脑实质）的无进展生存期（PFS）、CNS（软脑膜和脑实质）在第3、6和12个月的临床获益率（疾病稳定或改善）、6个月和12个月的总体生存率、LC缓解率（RR）和缓解持续时间（DoR）、三阴性（HER2-/ER-/PR-）乳腺癌受试者的OS 安全性：确定SNG1005的安全性和耐受性。

[Translation]

Compare the overall survival (OS) between the two groups; progression-free survival (PFS) in the CNS (leptomeninges and brain parenchyma), clinical benefit rate (disease stability or improvement) in the CNS (leptomeninges and brain parenchyma) at 3, 6, and 12 months, overall survival rate at 6 and 12 months, LC response rate (RR) and duration of response (DoR), OS in subjects with triple-negative (HER2-/ER-/PR-) breast cancer Safety: Determine the safety and tolerability of SNG1005.

Start Date-

Sponsor / Collaborator

XINOGEN （HONG KONG） PHARMA CO., LIMITED

[+1]

CTR20191654

/ RecruitingPhase 3

SNG1005对比研究者选择单药化疗治疗既往全脑放疗后脑实质进展的HER2阴性BCBM患者的多中心、随机对照、开放标签临床试验

[Translation] A multicenter, randomized, controlled, open-label clinical trial of SNG1005 versus investigator's choice of chemotherapy alone in patients with HER2-negative BCBM who have progressed in the brain parenchyma after prior whole-brain radiotherapy

比较两组的总生存期（OS）；比较两组的颅内、颅外的无进展生存期（PFS）；比较两组颅内、颅外的客观缓解率（ORR）；比较两组的颅内缓解持续时间（DoR）和第3和6个月DCR；比较两组颅外DoR；比较两组整体QoL

[Translation]

Compare the overall survival (OS) between the two groups; Compare the intracranial and extracranial progression-free survival (PFS) between the two groups; Compare the intracranial and extracranial objective response rate (ORR) between the two groups; Compare the intracranial duration of response (DoR) and DCR at 3 and 6 months between the two groups; Compare the extracranial DoR between the two groups; Compare the overall QoL between the two groups

Start Date24 May 2022

Sponsor / Collaborator

XINOGEN （HONG KONG） PHARMA CO., LIMITED

[+1]

100 Clinical Results associated with XINOGEN （HONG KONG） PHARMA CO., LIMITED

Login to view more data

0 Patents (Medical) associated with XINOGEN （HONG KONG） PHARMA CO., LIMITED

Login to view more data

100 Deals associated with XINOGEN （HONG KONG） PHARMA CO., LIMITED

Login to view more data

100 Translational Medicine associated with XINOGEN （HONG KONG） PHARMA CO., LIMITED

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data